Cargando…

Time Course and Mechanisms of Circulating Progenitor Cell Reduction in the Natural History of Type 2 Diabetes

OBJECTIVE: Reduction of bone marrow–derived circulating progenitor cells has been proposed as a novel mechanism of cardiovascular disease in type 2 diabetes. The present study was designed to describe the extent and potential mechanisms of progenitor cell reduction during the natural history of type...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fadini, Gian Paolo, Boscaro, Elisa, de Kreutzenberg, Saula, Agostini, Carlo, Seeger, Florian, Dimmeler, Stefanie, Zeiher, Andreas, Tiengo, Antonio, Avogaro, Angelo
Formato:	Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2010
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2858183/ https://www.ncbi.nlm.nih.gov/pubmed/20150295 http://dx.doi.org/10.2337/dc09-1999

Ejemplares similares

The Oral Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Increases Circulating Endothelial Progenitor Cells in Patients With Type 2 Diabetes: Possible role of stromal-derived factor-1α
por: Fadini, Gian Paolo, et al.
Publicado: (2010)

Procalcific Phenotypic Drift of Circulating Progenitor Cells in Type 2 Diabetes with Coronary Artery Disease
por: Fadini, Gian Paolo, et al.
Publicado: (2012)

Circulating Progenitor Cell Count for Cardiovascular Risk Stratification: A Pooled Analysis
por: Fadini, Gian Paolo, et al.
Publicado: (2010)

Amelioration of Glucose Control Mobilizes Circulating Pericyte Progenitor Cells in Type 2 Diabetic Patients with Microangiopathy
por: Fadini, Gian Paolo, et al.
Publicado: (2012)

Effects of androgens on endothelial progenitor cells in vitro and in vivo
por: Fadini, Gian Paolo, et al.
Publicado: (2009)

Diabetes Impairs Stem Cell and Proangiogenic Cell Mobilization in Humans
por: Fadini, Gian Paolo, et al.
Publicado: (2013)

Dipeptidyl-peptidase 4 Inhibition: Linking Metabolic Control to Cardiovascular Protection
por: Avogaro, Angelo, et al.
Publicado: (2014)

The Endothelium Abridges Insulin Resistance to Premature Aging
por: Avogaro, Angelo, et al.
Publicado: (2013)

Endothelial Dysfunction in Diabetes: The role of reparatory mechanisms
por: Avogaro, Angelo, et al.
Publicado: (2011)

Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial
por: Bonora, Benedetta Maria, et al.
Publicado: (2019)

It Is All in the Blood: The Multifaceted Contribution of Circulating Progenitor Cells in Diabetic Complications
por: Fadini, Gian Paolo, et al.
Publicado: (2012)

p66Shc gene expression in peripheral blood mononuclear cells and progression of diabetic complications
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Reduced levels of circulating progenitor cells in juvenile idiopathic arthritis are counteracted by anti TNF-α therapy
por: Martini, Giorgia, et al.
Publicado: (2015)

Downregulation of the Longevity-Associated Protein Sirtuin 1 in Insulin Resistance and Metabolic Syndrome: Potential Biochemical Mechanisms
por: de Kreutzenberg, Saula Vigili, et al.
Publicado: (2010)

Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets’ attainment in subjects with and without type 2 diabetes
por: Morieri, Mario Luca, et al.
Publicado: (2021)

A miR-125/Sirtuin-7 pathway drives the pro-calcific potential of myeloid cells in diabetic vascular disease
por: Vigili de Kreutzenberg, Saula, et al.
Publicado: (2022)

Circulating levels and characterization of microparticles in patients with different degrees of glucose tolerance
por: Giannella, Alessandra, et al.
Publicado: (2017)

Improved long-term cardiovascular outcomes after intensive versus standard screening of diabetic complications: an observational study
por: Morieri, Mario Luca, et al.
Publicado: (2019)

Improved prediction of long-term kidney outcomes in people with type 2 diabetes by levels of circulating haematopoietic stem/progenitor cells
por: Bonora, Benedetta Maria, et al.
Publicado: (2023)

Quantification of Circulating Endothelial Progenitor Cells Using the Modified ISHAGE Protocol
por: Schmidt-Lucke, Caroline, et al.
Publicado: (2010)

Glycaemic Control Achieves Sustained Increases of Circulating Endothelial Progenitor Cells in Patients Hospitalized for Decompensated Diabetes: An Observational Study
por: Bonora, Benedetta Maria, et al.
Publicado: (2022)

Wnt5a Increases Cardiac Gene Expressions of Cultured Human Circulating Progenitor Cells via a PKC Delta Activation
por: Koyanagi, Masamichi, et al.
Publicado: (2009)

Circulating Small Noncoding RNA Profiling as a Potential Biomarker of Atherosclerotic Plaque Composition in Type 1 Diabetes
por: Giannella, Alessandra, et al.
Publicado: (2023)

How to interpret the role of SDF-1α on diabetic complications during therapy with DPP-4 inhibitors
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

The Redox Enzyme p66Shc Contributes to Diabetes and Ischemia-Induced Delay in Cutaneous Wound Healing
por: Fadini, Gian Paolo, et al.
Publicado: (2010)

The dipeptidyl peptidase-4 inhibitor Saxagliptin improves function of circulating pro-angiogenic cells from type 2 diabetic patients
por: Poncina, Nicol, et al.
Publicado: (2014)

Telemedicine for the Clinical Management of Diabetes; Implications and Considerations After COVID-19 Experience
por: de Kreutzenberg, Saula Vigili
Publicado: (2022)

Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting System
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Pharmacovigilance Evaluation of the Association Between DPP-4 Inhibitors and Heart Failure: Stimulated Reporting and Moderation by Drug Interactions
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Managing diabetes in diabetic patients with COVID: where do we start from?
por: Avogaro, Angelo, et al.
Publicado: (2021)

Histone deacetylase activity is essential for the expression of HoxA9 and for endothelial commitment of progenitor cells
por: Rössig, Lothar, et al.
Publicado: (2005)

Long-Acting Injectable GLP-1 Receptor Agonists for the Treatment of Adults with Type 2 Diabetes: Perspectives from Clinical Practice
por: Morieri, Mario Luca, et al.
Publicado: (2020)

Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence
por: Bonora, Benedetta Maria, et al.
Publicado: (2020)

Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics
por: Morieri, Mario Luca, et al.
Publicado: (2020)

Response to Chia Siang Kow and colleagues
por: Avogaro, Angelo, et al.
Publicado: (2022)

PAR-4/Ca(2+)-calpain pathway activation stimulates platelet-derived microparticles in hyperglycemic type 2 diabetes
por: Giannella, Alessandra, et al.
Publicado: (2021)

SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system
por: Bonora, Benedetta Maria, et al.
Publicado: (2021)

Challenges and opportunities in real‐world evidence on the renal effects of sodium‐glucose cotransporter‐2 inhibitors
por: Fadini, Gian Paolo, et al.
Publicado: (2021)

The role of point-of-care 3-hydroxybutyrate testing in patients with type 2 diabetes undergoing coronary angiography
por: Vigili de Kreutzenberg, S., et al.
Publicado: (2017)

Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice
por: Avogaro, Angelo, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_p3fa787aq7pn17hh47o0jr5ip3